Featured Products

» Dr. Perlmutter's BrainSustain » Dr. Perlmutter's NeuroActives » Dr. Perlmutter's Vinpocetine » Dr. Perlmutter's DHA » BrainBuilder® 3.0

Books

» Raise a Smarter Child by Kindergarten » Better Brain Book » BrainRecovery.com » Dr. Perlmutter's Book Selections

Shop Online

» Online Store » Specials

What's Current?

» Conference Schedule » Media Schedule

Our Story

» About iNutritonals » About Dr. Perlmutter » Dr. Perlmutter's Blog » Testimonials

Healthy Info

» Healthy Living » BrainSustain Recipes » Articles Archive

Support

» Contact » FAQs

Physician Login

Username
Password
Forgot Password?

Visit and Read

Renegade
Neurologist

A Blog by Dr. Perlmutter

Visit Our Sponsor

Test Your Brain

iNutritionals donates 100% of after-tax profits to brain research.
501(c)(3)

Healthy Living

Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia

By Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD

Address: Parkinson's Disease Society Experimental Research Laboratories, Pharmacology Group, Biomedical Sciences Division, King's College London, UK
Source: Ann Neurol, 36(3):348-55 1994 Sep
Abstract

Reduced glutathione (GSH) and oxidized glutathione (GSSG) levels were measured in various brain areas (substantia nigra, putamen, caudate nucleus, globus pallidus, and cerebral cortex) from patients dying with Parkinson's disease, progressive supranuclear palsy, multiple-system atrophy, and Huntington's disease and from control subjects with no neuropathological changes in substantia nigra. GSH levels were reduced in substantia nigra in Parkinson's disease patients (40% compared to control subjects) and GSSG levels were marginally (29%) but insignificantly elevated; there were no changes in other brain areas. The only significant change in multiple-system atrophy was an increase of GSH (196%) coupled with a reduction of GSSG (60%) in the globus pallidus. The only change in progressive supranuclear palsy was a reduced level of GSH in the caudate nucleus (51%). The only change in Huntington's disease was a reduction of GSSG in the caudate nucleus (50%). Despite profound nigral cell loss in the substantia nigra in Parkinson's disease, multiple-system atrophy, and progressive supranuclear palsy, the level of GSH in the substantia nigra was significantly reduced only in Parkinson's disease. This suggests that the change in GSH in Parkinson's disease is not solely due to nigral cell death, or entirely explained by drug therapy, for multiple-system atrophy patients were also treated with levodopa. The altered GSH/GSSG ratio in the substantia nigra in Parkinson's disease is consistent with the concept of oxidative stress as a major component in the pathogenesis of nigral cell death in Parkinson's disease.

Publication Type: Journal Article ISSN 0364-5134
All Content Copyright © 2005-2008 iNutritionals™ All Rights Reserved.

* Any and all statements throughout the iNutritionals.com website have not been evaluated by the Food and Drug Administration. Any products shown on this website are not intended to diagnose, treat, cure or prevent any disease.

This information is provided for the use of physicians and other licensed health care practitioners only. This information is intended for physicians and other licensed health care providers to use as a basis for determining whether or not to recommend these products to their patients. This information is not for use by consumers. These products are not intended for use by consumers as a means to cure, treat, prevent, diagnose, or mitigate any disease or other medical condition.

iNutritionals, Inc. - 44 Buck Shoals Road, Suite F8 - Arden, NC 28704
Toll Free: 1-800-530-1982 - Phone: 828-681-0833 - Fax: 828-681-0824
www.inutritionals.com - info@inutritionals.com